In the wake of a big pharmaceutical news, Sun Pharmaceutical Industries, a leading Indian pharma company, announced through a massive $11.7 billion deal that it has successfully gained control of Organon, a major company dealing with women’s health and generic medicines. This development came at the same time as companies were involved in other high-stakes mergers and it is a strong indicator that big pharma companies are resorting to mergers to safeguard their profits, add value to their product portfolios, and to cope with the rapidly changing world market.

For Sun Pharma which has remained India’s leading pharmaceutical brand for quite some time, this new acquisition is one step towards changing its identity as purely a generic drug manufacturer to become a diversified pharmaceutical company that also deals with specialty medicines including branded drugs. In the year 2022, Sun Pharma turned into one of the top 20 global pharmaceutical companies in sales and the acquisition of Organon gives the company a strong footing through access of several well-accepted brands dealing with female reproductive health biosimilars as well as treating other diseases on a chronic basis.

This partnership goes beyond merely being a big money maker for both parties involved. It also highlights the current challenges facing the pharmaceutical industry. Patent expiration is affecting top-selling drugs which means that the manufacturers no longer make as much money on them, the rising cost of research and development and the pressure to scale up manufacturing and distribution are making it necessary for companies to collaborate. “This deal helps Sun Pharma speed up its transition from a purely generic drug manufacturer to a higher profit specialty and branded drug manufacturer, ” one analyst stated a few days ago. By concentrating the company on areas like women’s health where there is a lot of demand and where the needs of the patients are not yet properly addressed, Sun is putting itself in a good situation where it is a leading provider of medicines that address an individual’s health as well as a woman’s health.

Looking closely at the figures behind the announcement, the $11.75 billion valuation is not only one of the top deals with cross-border business activities involving Indian firms over the last few years, but it is also happening at a moment when the worldwide pharma deal activity has increased greatly, thanks in part to the availability of a lot of capital and strategic needs of the players involved. The acquisition is expected to give a big lift to Sun Pharmas top line and bottom line through the acquisition of a stable product portfolio. By getting rid of Organon’s dependency on fluctuating generic pricing, the merged entity will not only increase the stability of its operations but also enable it to invest in research and development of both new drugs and also in biosimilars.

Mind you the human angle and the potential of the acquisition to bring about very tangible effects on the lives of people in general. It is well-known that Organon has become an industry leader by tackling important health matters which include contraception, fertility issues, and menopause. It is these health areas that millions of women face every day. Through its experience in manufacturing medicines at affordable costs, Sun Pharma may make it possible for people in less developed regions to have access to these treatments, ultimately leading to worldwide advancement of health. Then again, the employees of both companies will closely watch how the new set-up would work, and with hope that the new situation will result not only in the preservation of their current jobs of making innovation and new products but also in the creation of newer employment.

Of course, there are still a few bumps in this road. First, multiple regulatory approvals should be granted in different regions that the two companies will conduct business. Antitrust agencies will scrutinize this kind of merger as an example of one of the major challenges of this deal. Also, there will be a need to find a solution for the cultural integration of a pharma giant that started its business in India with a company that is more oriented to a western market. Using the past acquisition experiences though it looks like there will be no doubt about the capability and the will that Sun Pharm will have on successfully carrying through the business integration.